Roivant Sciences Ltd. (ROIVW) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en London, United Kingdom. El CEO actual es Matthew Gline.
ROIVW tiene fecha de IPO 2021-09-27, 620 empleados a tiempo completo, cotiza en el NASDAQ Global Market, una capitalización de mercado de $1.97B.
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
